Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2018
At a glance
- Drugs Nivolumab (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.
- 07 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Mar 2017.
- 19 Jan 2017 New trial record